BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan M, Liu H, Wu NC, Wilson IA. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun 2021;538:192-203. [PMID: 33069360 DOI: 10.1016/j.bbrc.2020.10.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Matsunaga R, Tsumoto K. Addition of arginine hydrochloride and proline to the culture medium enhances recombinant protein expression in Brevibacillus choshinensis: The case of RBD of SARS-CoV-2 spike protein and its antibody. Protein Expression and Purification 2022. [DOI: 10.1016/j.pep.2022.106075] [Reference Citation Analysis]
2 Beshnova D, Fang Y, Du M, Sun Y, Du F, Ye J, Chen ZJ, Li B. Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.04.038] [Reference Citation Analysis]
3 Wilson IA, Stanfield RL. 50 Years of structural immunology. J Biol Chem 2021;296:100745. [PMID: 33957119 DOI: 10.1016/j.jbc.2021.100745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Tong P, Gautam A, Windsor IW, Travers M, Chen Y, Garcia N, Whiteman NB, McKay LGA, Storm N, Malsick LE, Honko AN, Lelis FJN, Habibi S, Jenni S, Cai Y, Rennick LJ, Duprex WP, McCarthy KR, Lavine CL, Zuo T, Lin J, Zuiani A, Feldman J, MacDonald EA, Hauser BM, Griffths A, Seaman MS, Schmidt AG, Chen B, Neuberg D, Bajic G, Harrison SC, Wesemann DR. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell 2021:S0092-8674(21)00884-9. [PMID: 34332650 DOI: 10.1016/j.cell.2021.07.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Liu H, Yuan M, Huang D, Bangaru S, Zhao F, Lee CD, Peng L, Barman S, Zhu X, Nemazee D, Burton DR, van Gils MJ, Sanders RW, Kornau HC, Reincke SM, Prüss H, Kreye J, Wu NC, Ward AB, Wilson IA. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe 2021;29:806-818.e6. [PMID: 33894127 DOI: 10.1016/j.chom.2021.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
6 Kombe Kombe AJ, Zahid A, Mohammed A, Shi R, Jin T. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. Front Mol Biosci 2021;8:670815. [PMID: 34136533 DOI: 10.3389/fmolb.2021.670815] [Reference Citation Analysis]
7 Kealy L, Good-jacobson KL. Advances in understanding the formation and fate of B-cell memory in response to immunization or infection. Oxford Open Immunology 2021;2:iqab018. [DOI: 10.1093/oxfimm/iqab018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Changrob S, Fu Y, Guthmiller JJ, Halfmann PJ, Li L, Stamper CT, Dugan HL, Accola M, Rehrauer W, Zheng NY, Huang M, Wang J, Erickson SA, Utset HA, Graves HM, Amanat F, Sather DN, Krammer F, Kawaoka Y, Wilson PC. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. mBio 2021;:e0297521. [PMID: 34781736 DOI: 10.1128/mBio.02975-21] [Reference Citation Analysis]
9 Reincke SM, Yuan M, Kornau HC, Corman VM, van Hoof S, Sánchez-Sendin E, Ramberger M, Yu W, Hua Y, Tien H, Schmidt ML, Schwarz T, Jeworowski LM, Brandl SE, Rasmussen HF, Homeyer MA, Stöffler L, Barner M, Kunkel D, Huo S, Horler J, von Wardenburg N, Kroidl I, Eser TM, Wieser A, Geldmacher C, Hoelscher M, Gänzer H, Weiss G, Schmitz D, Drosten C, Prüss H, Wilson IA, Kreye J. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Science 2022;375:782-7. [PMID: 35076281 DOI: 10.1126/science.abm5835] [Reference Citation Analysis]
10 Verkhivker GM, Di Paola L. Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. J Phys Chem B 2021;125:4596-619. [PMID: 33929853 DOI: 10.1021/acs.jpcb.1c00395] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
11 Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. SARS-CoV-2 Antiviral Therapy. Clin Microbiol Rev 2021;:e0010921. [PMID: 34319150 DOI: 10.1128/CMR.00109-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu H, Wilson IA. Protective neutralizing epitopes in SARS‐CoV‐2. Immunological Reviews. [DOI: 10.1111/imr.13084] [Reference Citation Analysis]
13 Yuan M, Zhu X, He WT, Zhou P, Kaku CI, Capozzola T, Zhu CY, Yu X, Liu H, Yu W, Hua Y, Tien H, Peng L, Song G, Cottrell CA, Schief WR, Nemazee D, Walker LM, Andrabi R, Burton DR, Wilson IA. A broad and potent neutralization epitope in SARS-related coronaviruses. bioRxiv 2022:2022. [PMID: 35313576 DOI: 10.1101/2022.03.13.484037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Vandergaast R, Carey T, Reiter S, Lathrum C, Lech P, Gnanadurai C, Haselton M, Buehler J, Narjari R, Schnebeck L, Roesler A, Sevola K, Suksanpaisan L, Bexon A, Naik S, Brunton B, Weaver SC, Rafael G, Tran S, Baum A, Kyratsous CA, Peng KW, Russell SJ. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers. mSphere 2021;6:e0017021. [PMID: 34077262 DOI: 10.1128/mSphere.00170-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Röltgen K, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, Yang F, Wirz OF, Solis D, Hoh RA, Wang A, Arunachalam PS, Colburg D, Zhao S, Haraguchi E, Lee AS, Shah MM, Manohar M, Chang I, Gao F, Mallajosyula V, Li C, Liu J, Shoura MJ, Sindher SB, Parsons E, Dashdorj NJ, Dashdorj ND, Monroe R, Serrano GE, Beach TG, Chinthrajah RS, Charville GW, Wilbur JL, Wohlstadter JN, Davis MM, Pulendran B, Troxell ML, Sigal GB, Natkunam Y, Pinsky BA, Nadeau KC, Boyd SD. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 2022;185:1025-1040.e14. [PMID: 35148837 DOI: 10.1016/j.cell.2022.01.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 22.0] [Reference Citation Analysis]
16 Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, Caniels TG, van Schooten J, Zhu X, Lee CD, Brouwer PJM, van Gils MJ, Sanders RW, Ward AB, Wilson IA. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity 2020;53:1272-1280.e5. [PMID: 33242394 DOI: 10.1016/j.immuni.2020.10.023] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 28.0] [Reference Citation Analysis]
17 Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity 2021;54:1841-1852.e4. [PMID: 34246326 DOI: 10.1016/j.immuni.2021.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Verkhivker GM, Agajanian S, Oztas DY, Gupta G. Allosteric Control of Structural Mimicry and Mutational Escape in the SARS-CoV-2 Spike Protein Complexes with the ACE2 Decoys and Miniprotein Inhibitors: A Network-Based Approach for Mutational Profiling of Binding and Signaling. J Chem Inf Model 2021;61:5172-91. [PMID: 34551245 DOI: 10.1021/acs.jcim.1c00766] [Reference Citation Analysis]
19 Feldman J, Bals J, Altomare CG, St Denis K, Lam EC, Hauser BM, Ronsard L, Sangesland M, Moreno TB, Okonkwo V, Hartojo N, Balazs AB, Bajic G, Lingwood D, Schmidt AG. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. bioRxiv 2021:2021. [PMID: 33594359 DOI: 10.1101/2021.02.02.429458] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
20 Onodera T, Kita S, Adachi Y, Moriyama S, Sato A, Nomura T, Sakakibara S, Inoue T, Tadokoro T, Anraku Y, Yumoto K, Tian C, Fukuhara H, Sasaki M, Orba Y, Shiwa N, Iwata N, Nagata N, Suzuki T, Sasaki J, Sekizuka T, Tonouchi K, Sun L, Fukushi S, Satofuka H, Kazuki Y, Oshimura M, Kurosaki T, Kuroda M, Matsuura Y, Suzuki T, Sawa H, Hashiguchi T, Maenaka K, Takahashi Y. A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. Immunity 2021;54:2385-2398.e10. [PMID: 34508662 DOI: 10.1016/j.immuni.2021.08.025] [Reference Citation Analysis]
21 Yang M, Li J, Huang Z, Li H, Wang Y, Wang X, Kang S, Huang X, Wu C, Liu T, Jia Z, Liang J, Yuan X, He S, Chen X, Zhou Z, Chen Q, Liu S, Li J, Zheng H, Liu X, Li K, Yao X, Lang B, Liu L, Liao HX, Chen S. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Microbiol Spectr 2021;9:e0135221. [PMID: 34643438 DOI: 10.1128/Spectrum.01352-21] [Reference Citation Analysis]
22 Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs 2022. [PMID: 35476216 DOI: 10.1007/s40259-022-00529-7] [Reference Citation Analysis]
23 Zhou X, Ma F, Xie J, Yuan M, Li Y, Shaabani N, Zhao F, Huang D, Wu NC, Lee CD, Liu H, Li J, Chen Z, Hong Y, Liu WH, Xiao N, Burton DR, Tu H, Li H, Chen X, Teijaro JR, Wilson IA, Xiao C, Huang Z. Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. Cell Rep 2021;35:109109. [PMID: 33932326 DOI: 10.1016/j.celrep.2021.109109] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cheng MH, Krieger JM, Banerjee A, Xiang Y, Kaynak B, Shi Y, Arditi M, Bahar I. Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. iScience 2022;25:103939. [PMID: 35194576 DOI: 10.1016/j.isci.2022.103939] [Reference Citation Analysis]
25 Schoenle MV, Li Y, Yuan M, Clarkson MW, Wilson IA, Peti W, Page R. NMR Based SARS-CoV-2 Antibody Screening. J Am Chem Soc 2021;143:7930-4. [PMID: 34018723 DOI: 10.1021/jacs.1c03945] [Reference Citation Analysis]
26 Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, van Gils MJ, Sanders RW, Burton DR, Reincke SM, Prüss H, Kreye J, Nemazee D, Ward AB, Wilson IA. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. bioRxiv 2021:2021. [PMID: 33619487 DOI: 10.1101/2021.02.16.430500] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 27.0] [Reference Citation Analysis]
27 Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021. [PMID: 34535792 DOI: 10.1038/s41576-021-00408-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
28 Niu L, Wittrock KN, Clabaugh GC, Srivastava V, Cho MW. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. Front Immunol 2021;12:647934. [PMID: 33995366 DOI: 10.3389/fimmu.2021.647934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
29 Röltgen K, Nielsen SCA, Arunachalam PS, Yang F, Hoh RA, Wirz OF, Lee AS, Gao F, Mallajosyula V, Li C, Haraguchi E, Shoura MJ, Wilbur JL, Wohlstadter JN, Davis MM, Pinsky BA, Sigal GB, Pulendran B, Nadeau KC, Boyd SD. mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. medRxiv 2021:2021. [PMID: 33851181 DOI: 10.1101/2021.04.05.21254952] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
30 Kunkel G, Madani M, White SJ, Verardi PH, Tarakanova A. Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape. Biophys J 2021:S0006-3495(21)00956-5. [PMID: 34767789 DOI: 10.1016/j.bpj.2021.11.009] [Reference Citation Analysis]
31 Lyubavina NA, Saltsev SG, Menkov NV, Tyurikova LV, Plastinina SS, Shonia ML, Tulichev AA, Milyutina MY, Makarova EV. Immunological Approaches to the Treatment of New Coronavirus Infection (Review). Sovrem Tekhnologii Med 2021;13:81-99. [PMID: 34603758 DOI: 10.17691/stm2021.13.3.09] [Reference Citation Analysis]
32 Kashani NR, Azadbakht J, Ehteram H, Kashani HH, Rajabi-moghadam H, Ahmad E, Nikzad H, Hosseini ES. Molecular and Clinical Investigation of COVID-19: From Pathogenesis and Immune Responses to Novel Diagnosis and Treatment. Front Mol Biosci 2022;9:770775. [DOI: 10.3389/fmolb.2022.770775] [Reference Citation Analysis]
33 Moerman A, Vernelen K, China B, Capron A, Bossche DVD, Mariën J, Ariën KK, Van Acker J, Delforge ML, Reynders M, Boel A, Depypere M, Van Gasse N, Vijgen S, Brauner J, Dujardin B, Padalko E. Importance of anti-SARS-CoV-2 assay antigenic composition as revealed by the results of the Belgian external quality assessment (EQA) scheme. Diagn Microbiol Infect Dis 2021;102:115561. [PMID: 34773801 DOI: 10.1016/j.diagmicrobio.2021.115561] [Reference Citation Analysis]
34 Yi C, Sun X, Lin Y, Gu C, Ding L, Lu X, Yang Z, Zhang Y, Ma L, Gu W, Qu A, Zhou X, Li X, Xu J, Ling Z, Xie Y, Lu H, Sun B. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. Genome Med 2021;13:164. [PMID: 34649620 DOI: 10.1186/s13073-021-00985-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Urbán S, Paragi G, Burián K, McLean GR, Virok DP. Identification of similar epitopes between severe acute respiratory syndrome coronavirus-2 and Bacillus Calmette-Guérin: potential for cross-reactive adaptive immunity. Clin Transl Immunology 2020;9:e1227. [PMID: 33318797 DOI: 10.1002/cti2.1227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
36 Mejdani M, Haddadi K, Pham C, Mahadevan R. SARS-CoV-2 receptor-binding mutations and antibody contact sites. Antib Ther 2021;4:149-58. [PMID: 34386694 DOI: 10.1093/abt/tbab015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: Characteristics and prevention. MedComm (2020) 2021. [PMID: 34957469 DOI: 10.1002/mco2.110] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Valdes-Balbin Y, Santana-Mederos D, Paquet F, Fernandez S, Climent Y, Chiodo F, Rodríguez L, Sanchez Ramirez B, Leon K, Hernandez T, Castellanos-Serra L, Garrido R, Chen GW, Garcia-Rivera D, Rivera DG, Verez-Bencomo V. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. ACS Cent Sci 2021;7:757-67. [PMID: 34075345 DOI: 10.1021/acscentsci.1c00216] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 28.0] [Reference Citation Analysis]
39 Castro Dopico X, Ols S, Loré K, Karlsson Hedestam GB. Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med 2021. [PMID: 34352148 DOI: 10.1111/joim.13372] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Cao Q, Wu S, Xiao C, Chen S, Chi X, Cui X, Tang H, Su W, Zheng Y, Zhong J, Li Z, Li F, Chen H, Hou L, Wang H, Wen W. Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization. Cell Discov 2021;7:64. [PMID: 34373443 DOI: 10.1038/s41421-021-00300-2] [Reference Citation Analysis]
41 Khan MI, Baig MH, Mondal T, Alorabi M, Sharma T, Dong JJ, Cho JY. Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. Viruses 2021;13:2295. [PMID: 34835101 DOI: 10.3390/v13112295] [Reference Citation Analysis]
42 Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, Shurin MR. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr 2021;9:e0034121. [PMID: 34346750 DOI: 10.1128/Spectrum.00341-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Yin R, Guest JD, Taherzadeh G, Gowthaman R, Mittra I, Quackenbush J, Pierce BG. Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants. PLoS Comput Biol 2021;17:e1009380. [PMID: 34491988 DOI: 10.1371/journal.pcbi.1009380] [Reference Citation Analysis]
44 Qiang M, Ma P, Li Y, Liu H, Harding A, Min C, Wang F, Liu L, Yuan M, Ji Q, Tao P, Shi X, Li Z, Li T, Wang X, Zhang Y, Wu NC, Lee CD, Zhu X, Gilbert-Jaramillo J, Zhang C, Saxena A, Huang X, Wang H, James W, Dwek RA, Wilson IA, Yang G, Lerner RA. Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago. Adv Sci (Weinh) 2022;9:e2102181. [PMID: 34716683 DOI: 10.1002/advs.202102181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Ishii H, Nomura T, Yamamoto H, Nishizawa M, Thu Hau TT, Harada S, Seki S, Nakamura-Hoshi M, Okazaki M, Daigen S, Kawana-Tachikawa A, Nagata N, Iwata-Yoshikawa N, Shiwa N, Suzuki T, Park ES, Ken M, Onodera T, Takahashi Y, Kusano K, Shimazaki R, Suzaki Y, Ami Y, Matano T. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses. Cell Rep Med 2022;3:100520. [PMID: 35233545 DOI: 10.1016/j.xcrm.2022.100520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
46 Tan TJC, Yuan M, Kuzelka K, Padron GC, Beal JR, Chen X, Wang Y, Rivera-Cardona J, Zhu X, Stadtmueller BM, Brooke CB, Wilson IA, Wu NC. Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain. bioRxiv 2021:2021. [PMID: 33532781 DOI: 10.1101/2021.01.26.428356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Beilhack G, Monteforte R, Frommlet F, Gaggl M, Strassl R, Vychytil A. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort. Front Immunol 2021;12:780594. [PMID: 34925359 DOI: 10.3389/fimmu.2021.780594] [Reference Citation Analysis]
48 Singh N, Villoutreix BO. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Comput Struct Biotechnol J 2021;19:2537-48. [PMID: 33936562 DOI: 10.1016/j.csbj.2021.04.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Leigh KE, Modis Y. Imaging and visualizing SARS-CoV-2 in a new era for structural biology. Interface Focus 2021;11:20210019. [PMID: 34956593 DOI: 10.1098/rsfs.2021.0019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Liu H, Yuan M, Huang D, Bangaru S, Lee CD, Peng L, Zhu X, Nemazee D, van Gils MJ, Sanders RW, Kornau HC, Reincke SM, Prüss H, Kreye J, Wu NC, Ward AB, Wilson IA. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. bioRxiv 2021:2021. [PMID: 33594361 DOI: 10.1101/2021.02.11.430866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
51 [DOI: 10.1101/2021.01.31.428824] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Martí D, Martín-Martínez E, Torras J, Bertran O, Turon P, Alemán C. In silico antibody engineering for SARS-CoV-2 detection. Comput Struct Biotechnol J 2021;19:5525-34. [PMID: 34642596 DOI: 10.1016/j.csbj.2021.10.010] [Reference Citation Analysis]
53 Deshpande A, Harris BD, Martinez-sobrido L, Kobie JJ, Walter MR. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Front Immunol 2021;12:691715. [DOI: 10.3389/fimmu.2021.691715] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
54 [DOI: 10.1101/2021.03.21.436311] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Jutel M, Torres MJ, Palomares O, Akdis CA, Eiwegger T, Untersmayr E, Barber D, Zemelka-Wiacek M, Kosowska A, Palmer E, Vieths S, Mahler V, Canonica WG, Nadeau K, Shamji MH, Agache I. COVID-19  vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations. Allergy 2022. [PMID: 35147230 DOI: 10.1111/all.15252] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Graham C, Seow J, Huettner I, Khan H, Kouphou N, Acors S, Winstone H, Pickering S, Pedro Galao R, Jose Lista M, Jimenez-Guardeno JM, Laing AG, Wu Y, Joseph M, Muir L, Ng WM, Duyvesteyn HME, Zhao Y, Bowden TA, Shankar-Hari M, Rosa A, Cherepanov P, McCoy LE, Hayday AC, Neil SJD, Malim MH, Doores KJ. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike. bioRxiv 2021:2021. [PMID: 33564766 DOI: 10.1101/2021.02.03.429355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 13.0] [Reference Citation Analysis]
57 Mittal A, Khattri A, Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. PLoS Pathog 2022;18:e1010260. [PMID: 35176090 DOI: 10.1371/journal.ppat.1010260] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
58 Torres JL, Ozorowski G, Andreano E, Liu H, Copps J, Piccini G, Donnici L, Conti M, Planchais C, Planas D, Manganaro N, Pantano E, Paciello I, Pileri P, Bruel T, Montomoli E, Mouquet H, Schwartz O, Sala C, De Francesco R, Wilson IA, Rappuoli R, Ward AB. Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proc Natl Acad Sci U S A 2022;119:e2120976119. [PMID: 35549549 DOI: 10.1073/pnas.2120976119] [Reference Citation Analysis]
59 Wu CR, Yin WC, Jiang Y, Xu HE. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacol Sin 2022. [PMID: 35058587 DOI: 10.1038/s41401-021-00851-w] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
60 Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, van Gils MJ, Sanders RW, Burton DR, Reincke SM, Prüss H, Kreye J, Nemazee D, Ward AB, Wilson IA. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science 2021;373:818-23. [PMID: 34016740 DOI: 10.1126/science.abh1139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 35] [Article Influence: 23.0] [Reference Citation Analysis]
61 Biswas S, Mahmud S, Mita MA, Afrose S, Hasan MR, Sultana Shimu MS, Saleh MA, Mostafa-hedeab G, Alqarni M, Obaidullah AJ, Batiha GE. Molecular Docking and Dynamics Studies to Explore Effective Inhibitory Peptides Against the Spike Receptor Binding Domain of SARS-CoV-2. Front Mol Biosci 2022;8:791642. [DOI: 10.3389/fmolb.2021.791642] [Reference Citation Analysis]
62 Gorchakov AA, Kulemzin SV, Guselnikov SV, Baranov KO, Belovezhets TN, Mechetina LV, Volkova OY, Najakshin AM, Chikaev NA, Chikaev AN, Solodkov PP, Larichev VF, Gulyaeva MA, Markhaev AG, Kononova YV, Alekseyev AY, Shestopalov AM, Yusubalieva GM, Klypa TV, Ivanov AV, Valuev-Elliston VT, Baklaushev VP, Taranin AV. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. Cell Discov 2021;7:96. [PMID: 34667147 DOI: 10.1038/s41421-021-00340-8] [Reference Citation Analysis]
63 Hartard C, Chaqroun A, Settembre N, Gauchotte G, Lefevre B, Marchand E, Mazeaud C, Nguyen DT, Martrille L, Koscinski I, Malikov S, Schvoerer E. Multiorgan and Vascular Tropism of SARS-CoV-2. Viruses 2022;14:515. [DOI: 10.3390/v14030515] [Reference Citation Analysis]
64 Burnett DL, Jackson KJL, Langley DB, Aggrawal A, Stella AO, Johansen MD, Balachandran H, Lenthall H, Rouet R, Walker G, Saunders BM, Singh M, Li H, Henry JY, Jackson J, Stewart AG, Witthauer F, Spence MA, Hansbro NG, Jackson C, Schofield P, Milthorpe C, Martinello M, Schulz SR, Roth E, Kelleher A, Emery S, Britton WJ, Rawlinson WD, Karl R, Schäfer S, Winkler TH, Brink R, Bull RA, Hansbro PM, Jäck HM, Turville S, Christ D, Goodnow CC. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. Immunity 2021:S1074-7613(21)00457-X. [PMID: 34788600 DOI: 10.1016/j.immuni.2021.10.019] [Reference Citation Analysis]
65 Bao L, Zhang C, Lyu J, Yi P, Shen X, Tang B, Zhao H, Ren B, Kuang Y, Zhou L, Li Y. Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker. J Appl Microbiol 2021. [PMID: 34706134 DOI: 10.1111/jam.15340] [Reference Citation Analysis]
66 Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. Front Immunol 2022;13:801522. [PMID: 35222380 DOI: 10.3389/fimmu.2022.801522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Martí D, Alsina M, Alemán C, Bertran O, Turon P, Torras J. Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein and various specific monoclonal antibodies. Biochimie 2021:S0300-9084(21)00249-2. [PMID: 34710552 DOI: 10.1016/j.biochi.2021.10.013] [Reference Citation Analysis]
68 Kumar Paul G, Mahmud S, Aldahish AA, Afroze M, Biswas S, Briti Ray Gupta S, Hasan Razu M, Zaman S, Salah Uddin M, Nahari MH, Merae Alshahrani M, Abdul Rahman Alshahrani M, Khan M, Abu Saleh M. Computational screening and biochemical analysis of Pistacia integerrima and Pandanus odorifer plants to find effective inhibitors against Receptor-Binding domain (RBD) of the spike protein of SARS-Cov-2. Arab J Chem 2022;15:103600. [PMID: 34909068 DOI: 10.1016/j.arabjc.2021.103600] [Reference Citation Analysis]
69 Kim SH, Kearns FL, Rosenfeld MA, Casalino L, Papanikolas MJ, Simmerling C, Amaro RE, Freeman R. GlycoGrip: Cell Surface-Inspired Universal Sensor for Betacoronaviruses. ACS Cent Sci 2022;8:22-42. [PMID: 35106370 DOI: 10.1021/acscentsci.1c01080] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
70 Wu NC, Yuan M, Bangaru S, Huang D, Zhu X, Lee CD, Turner HL, Peng L, Yang L, Burton DR, Nemazee D, Ward AB, Wilson IA. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog 2020;16:e1009089. [PMID: 33275640 DOI: 10.1371/journal.ppat.1009089] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
71 Tan TJC, Yuan M, Kuzelka K, Padron GC, Beal JR, Chen X, Wang Y, Rivera-Cardona J, Zhu X, Stadtmueller BM, Brooke CB, Wilson IA, Wu NC. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nat Commun 2021;12:3815. [PMID: 34155209 DOI: 10.1038/s41467-021-24123-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]